Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients

Background Morbidly obese patients (BMI > 40 kg/m 2 ) are at increased risk for venous thromboembolism, especially after surgery. Despite limited evidence, morbidly obese patients are often administered a double dose of nadroparin for thromboprophylaxis compared to non-obese patients. The aim of...

Full description

Saved in:
Bibliographic Details
Published in:Obesity surgery 2012-05, Vol.22 (5), p.791-796
Main Authors: Diepstraten, Jeroen, Hackeng, Christian M., van Kralingen, Simone, Zapletal, Jiri, van Dongen, Eric P. A., Wiezer, René J., van Ramshorst, Bert, Knibbe, Catherijne A. J.
Format: Article
Language:English
Subjects:
Anticoagulants
Clinical Research
Drug dosages
Medicine
Medicine & Public Health
Obesity
Surgery
Thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Morbidly obese patients (BMI > 40 kg/m 2 ) are at increased risk for venous thromboembolism, especially after surgery. Despite limited evidence, morbidly obese patients are often administered a double dose of nadroparin for thromboprophylaxis compared to non-obese patients. The aim of this study was to evaluate the influence of different body size descriptors on anti-Xa levels after a double dose of nadroparin (5,700 IU) in morbidly obese patients. Methods In 27 morbidly obese patients with a mean total body weight of 148 kg (range 107–260 kg), anti-Xa levels were determined peri-operatively until 24 h after administration of a subcutaneous dose of 5,700 IU of nadroparin. Results Anti-Xa level 4 h after administration (A 4h , mean 0.22 ± 0.07 IU/ml) negatively correlated strongly with lean body weight ( r  = −0.66 ( p  
ISSN:0960-8923
1708-0428
DOI:10.1007/s11695-012-0602-7